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Summary
Background Outcomes for people with first-episode psychosis are highly heterogeneous. Few reliable validated 
methods are available to predict the outcome for individual patients in the first clinical contact. In this study, we 
aimed to build multivariable prediction models of 1-year remission and recovery outcomes using baseline clinical 
variables in people with first-episode psychosis.
Methods In this machine learning approach, we applied supervised machine learning, using regularised regression and 
nested leave-one-site-out cross-validation, to baseline clinical data from the English Evaluating the Development and 
Impact of Early Intervention Services (EDEN) study (n=1027), to develop and internally validate prediction models at 
1-year follow-up. We assessed four binary outcomes that were recorded at 1 year: symptom remission, social recovery, 
vocational recovery, and quality of life (QoL). We externally validated the prediction models by selecting from the top 
predictor variables identified in the internal validation models the variables shared with the external validation datasets 
comprised of two Scottish longitudinal cohort studies (n=162) and the OPUS trial, a randomised controlled trial of 
specialised assertive intervention versus standard treatment (n=578).
Findings The performance of prediction models was robust for the four 1-year outcomes of symptom remission (area 
under the receiver operating characteristic curve [AUC] 0·703, 95% CI 0·664–0·742), social recovery (0·731, 
0·697–0·765), vocational recovery (0·736, 0·702–0·771), and QoL (0·704, 0·667–0·742; p<0·0001 for all outcomes), 
on internal validation. We externally validated the outcomes of symptom remission (AUC 0·680, 95% CI 0·587–0·773), 
vocational recovery (0·867, 0·805–0·930), and QoL (0·679, 0·522–0·836) in the Scottish datasets, and symptom 
remission (0·616, 0·553–0·679), social recovery (0·573, 0·504–0·643), vocational recovery (0·660, 0·610–0·710), and 
QoL (0·556, 0·481–0·631) in the OPUS dataset.
Interpretation In our machine learning analysis, we showed that prediction models can reliably and prospectively 
identify poor remission and recovery outcomes at 1 year for patients with first-episode psychosis using baseline 
clinical variables at first clinical contact.
Funding Lundbeck Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 
4.0 license.
Introduction
Psychosis is an illness with an early first onset, 
occurring usually in young people and with an inci­
dence of 31 per 100 000 person­years.1 Patients with 
first­episode psychosis have heterogeneity of out­
comes, with a 58% prevalence of remission and 38% of 
recovery.2 The identification of individual­patient out­
comes at initial clinical contact might help to per son­
alise treatment and lead to improved use of resources 
for those most in need or likely to respond to treatment.3 
However, few validated tools are available for the 
accurate early identification of patients with good or 
poor outcomes.
Previous observational studies have identified predictors 
of outcomes at the group level, including sociodemo­
graphic factors, clinical and treatment response variables, 
comorbidity, and functional and cognitive deficits,2,4,5 with 
inconsistent reliability.6 More clarity is needed on how 
to apply group­level factors to an individual level of 
prediction. An approach that can be applied to stratify the 
individualised risk of a poor outcome at the initial clinical 
contact is required. One solution is the use of machine 
learning, in which algorithms can sift through a large 
array of predictor variables and detect complex high 
dimensional interactions that can reliably predict 
individual­patient outcomes.7
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Two models developed for outcome prediction in 
psychosis using baseline variables have been published.8,9 
Koutsouleris and colleagues8 used machine learning to 
predict 4­week and 52­week functional outcomes in 
patients with first­episode psychosis to a 75·0% (for 
4 weeks) and 73·8% (for 52 weeks) test­fold balanced 
accuracy (ie, average accuracy across the ten folds) on 
repeated nested internal cross­validation, with use of 
data from a randomised control study (n=334); however, 
this model was not externally validated. Leighton and 
colleagues9 developed 1­year remission and vocational 
recovery prediction models on 83 patients with first­
episode psychosis and externally validated their models 
on 79 patients with the same condition; however, this 
study was limited by the small sample size.
To overcome the two major limitations of these previous 
studies (no external validation and small sample size), we 
aimed to apply a machine learning approach using one of 
the largest longitudinal cohort studies of patients with 
first­episode psychosis (n=1027), for model development 
and internal validation, and data from a large randomised 
control trial (n=578) and two longitudinal cohort studies 
(totalling 162 patients), for external validation. We 
developed prediction models for multiple outcomes, 
including symptom remission and functional recovery 
(social recovery, vocational recovery, and quality of life) at 
1 year after first­episode psychosis.
Methods
Study design and sources of data
In this machine learning approach, we used data from 
several sources: the National EDEN studies,10 two Scottish 
validation datasets,9,11 and the OPUS trial.12 The National 
EDEN studies are a longitudinal naturalistic study of 
1027 patients with first­episode psychosis recruited from 
14 early intervention services across the National Health 
Service (NHS) in England (2005–10); the methods and 
baseline characteristics have been outlined previously.10 
The Scottish validation datasets were two longitudinal 
cohort studies of patients with first­episode psychosis: the 
Compassionate Recovery: Individualised Support in early 
Psychosis (CR:ISP) study9 of 83 patients in NHS Greater 
Glasgow & Clyde (2011–14), and an earlier study11 of 
79 patients in NHS Glasgow and NHS Edinburgh 
(2006–09). The metho dologies and baseline characteristics 
of these studies have been outlined previously.9,11 The 
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Research in context
Evidence before this study
In patients with first-episode psychosis, prediction of remission 
and recovery outcomes is an important goal during initial clinical 
contact. These patients have heterogeneous outcomes, even 
with standardised interventions. Targeting extended or more 
intensive treatment to patients with poorer prognosis might 
lead to better outcomes. Previous studies have identified several 
group-level predictors, including poor premorbid adjustment, 
history of developmental disorder, symptom severity at baseline, 
and duration of untreated psychosis, as predictors of poor 
clinical, functional, and cognitive outcomes. Such group-level 
differences are not always replicated at the individual level, and 
how to combine the group-level factors for individualised 
prediction is unclear. We searched PubMed from inception to 
March 12, 2019, using the terms “psychosis” or “first episode 
psychosis” or “schizophrenia” AND “prediction” AND “outcome” 
in any field, with no language restrictions. We retrieved 
470 articles, of which, after excluding articles not related to 
multivariable prediction of outcomes based on baseline clinical 
variables, we identified two articles that have published models 
for outcome prediction in psychosis using baseline variables. 
One study had developed an internally cross-validated model for 
prediction of functional outcomes in a large sample, but this 
model was not externally validated on an independent sample. 
The other study developed remission and recovery prediction 
models on a small sample from a longitudinal cohort study, and 
externally validated the models on patients from a different 
cohort study. Additionally, examples exist of outcome prediction 
models that have been internally cross-validated and externally 
validated for depression.
Added value of this study
To our knowledge, our study provides the first reliable evidence 
for the usefulness of machine learning to develop outcome 
prediction models, using baseline variables at first clinical 
contact, in a large sample of patients with first-episode 
psychosis. The models use baseline clinical and demographic 
data, rather than neuroimaging or other biomarkers, and, 
as such, are more accessible in a clinical setting for potential 
future applications. Our results were validated by the methods 
that we used, including internal–external validation of the 
outcome prediction models developed on data from a large 
multicentre cohort study and external validation on a small 
cohort study of patients with first-episode psychosis and a large 
randomised controlled trial of patients with first-episode 
psychosis. Our study attempted to develop outcome prediction 
models for multiple outcomes (clinical, recovery, and quality of 
life), although a single model might be useful to predict 
multiple outcomes, albeit with reduced accuracy.
Implications of all the available evidence
Our study, and the two previous studies, showed that machine 
learning techniques applied to baseline clinical and 
demographic data can aid in the prediction of remission and 
recovery outcomes for patients with first-episode psychosis at 
first clinical contact. This approach can be extended to include 
other sources of data (neuroimaging data, immune biomarkers, 
and so on), which might enhance model performance. The next 
step before implementation into routine clinical practice would 
be to investigate the usefulness of the prediction models in 
prospective controlled trials.
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OPUS trial12 (NCT00157313) was a randomised controlled 
trial of 578 patients with first­episode psychosis recruited 
from all inpatient and outpatient mental health services in 
Copenhagen (Copenhagen Hospital Corporation) and 
Aarhus County, Denmark. OPUS assessed standard 
(n=272) versus specialised assertive intervention integrated 
treatment (n=275; January, 1998, to December, 2000). The 
methods and baseline characteristics of OPUS have been 
outlined previously.12 Local ethics committees approved the 
studies and the trial. We have adhered to the transparent 
reporting of a multivariable prediction model for individual 
prognosis or diagnosis (TRIPOD) statement.13
With data from the EDEN studies, we developed four 
predictive models for each of the outcomes assessed in our 
study and internally validated the models by nested leave­
one­site­out cross­validation (LOSOCV). Subsequently, we 
identified shared variables (from the top predictor variables 
from the internally validated models) between the EDEN 
studies and the Scottish datasets and between the EDEN 
studies and OPUS trial. We used these shared variables to 
build separate prediction models for external validation on 
the Scottish datasets and OPUS trial.
The key differences between EDEN (development) and 
Scottish (validation) datasets were the setting (EDEN was 
done in NHS England, whereas the Scottish datasets 
were from studies done in NHS Scotland) and study 
period (2005–10 in EDEN, 2011–14 and 2006–09 in the 
Scottish datasets). Both NHS England and NHS Scotland 
are free at the point of delivery. The key differences 
between EDEN and the other validation dataset (OPUS) 
were the setting (England vs Denmark, but both free 
at the point of delivery), study period (2005–10 vs 
January, 1998 to December, 2000 in OPUS), study type 
(naturalistic in EDEN, for which everyone received early 
intervention, vs randomised clinical trial in OPUS, for 
which early intervention was compared with treatment 
as usual), and inclusion criteria (participants were aged 
14–35 years with a first presentation of psychotic 
symptoms in EDEN, whereas in OPUS, participants 
were aged 18–45 years with a diagnosis in the 
schizophrenia spectrum according to the International 
Classification of Diseases tenth edition codes in the 
F2 category, and participants in OPUS had not been 
given antipsychotic drugs for more than 12 weeks of 
continuous treatment). The inclusion and exclusion 
criteria for all three studies have been provided in the 
appendix (p 1).
Outcome variables
For EDEN, Scottish, and OPUS studies, assessments 
of predictors and outcomes were done by research 
assistants not directly involved in clinical care. We assessed 
four binary outcomes that were recorded at 1 year: symptom 
remission, meeting the Positive and Negative Syndrome 
Scale in Schizophrenia (PANSS) criteria at both 6 months 
and 1 year;14 social recovery, achieving a Global Assess ment 
of Functioning (GAF) score (range 0–100) of 65 or higher 
in EDEN, and a mean GAF symptoms and GAF disability 
score of 65 or higher in OPUS;15 vocational recovery, 
assessing whether participants were in employment, 
education, or training;16 and quality of life (QoL), assessed 
with the 3­level European QoL 5 Dimensions Index 
(EQ­5D­3L) time trade­off index based on UK population 
norms and dichotomised to greater than median (0·848)17 
in EDEN, the WHO QoL 26­item18 instrument with total 
score dichotomised to greater than median (88) in the 
2006–09 Scottish study, and the Lancashire QoL score19 
dichotomised at the median (43·5) in OPUS. We chose 
operationalised criteria for symptom remission14 and 
included the three outcome measures for recovery to cover 
a broader patient­centred experience of recovery. Social 
recovery was not measured in the Scottish studies.
Statistical analysis
The EDEN study was powered for duration of untreated 
psychosis. OPUS was powered for positive symptoms See Online for appendix
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PANSS P3—hallucinatory behaviour
GAF total
Adjusted DUP in days
Voluntary admission at baseline
PAS client late adolescence sociability 
withdrawal
PAS client general highest functioning 
achieved in life
Qualification level
PAS client general energy level
PANSS P2—conceptual disorganisation
Most serious self-harm is with premeditation 
of 3 h or less
Hours a week doing leisure activities
PANSS N4—passive social withdrawal
Housing type is own home or parents’ home
Most serious self-harm is with knife or razor
Community psychiatric nurse contact in last 
3 months
History of LSD use
History of ketamine use
Any time spent per week doing leisure 
activities
PAS client late adolescence social sexual 
aspects
PANSS G9—unusual thought content
Was help sought in the prodromal phase?
Insight scale awareness of symptoms
Main income source is salary or wage
Help by friend or relative around the house 
in last 3 months
Any first degree relative with schizophrenia
Family member suggested care
Years of schooling
In education at baseline 
Most serious self-harm is with 
premeditation—not applicable
Never self-harmed
GAF total
Main income source is salary or wage
PAS client late adolescence social sexual aspects
GAF disability total
Qualification level
History of ketamine use
Main income source is state benefits
PANSS P2—conceptual disorganisation
PANSS P4—excitement 
History of amphetamine use
PAS client general job change interrupted school attendance
Atheist or agnostic
PAS client late adolescence sociability withdrawal
PANSS P3—hallucinatory behaviour
PAS client general employed or at school
Voluntary admission at baseline
PANSS P7—hostility
EQ-5D-3L health thermometer
PANSS N4—passive social withdrawal
Help by friends or relatives around the house in last 3 months
PANSS G11—poor attention
In paid employment at baseline
Community psychiatric nurse contact in last 3 months
PANSS G8—uncooperativeness
 
Previous secondary psychiatric care
Mother tongue is language other than English but has good 
knowledge of English
GAF symptoms total
EQ-5D-3L UK TTO index
History of possible developmental disorder
Contact with criminal justice services in last 3 months
Any help from friends or relatives in last 3 months
Most serious self-harm is with overdose, drugs or alcohol
First contact with EIS was facilitated by agency other than 
health, social care, criminal justice, or religious organisation
PAS client general education
(Figure 1 continues on next page)
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according to the Scale for Assessment of Positive 
Symptoms (SAPS). The 2006–09 Scottish study was 
powered for the strength of association between duration 
of untreated psychosis and psychiatric symptomatology. 
The 2011–14 Scottish study was powered for positive and 
negative symptoms. Because our study is a post­hoc 
analysis, a sample size calculation is not applicable.
Studies with missing outcome data were removed from 
the analysis. Regarding predictor selection, during data 
pre­processing in EDEN, all 266 baseline social, 
demographic, and clinical predictor variables were centred 
and scaled, variables with zero variance and near­zero 
variance were removed, and variables with more than 
20% of missing data were excluded. For the remaining 
163 (61%) of predictor variables (appendix pp 2–6), 
missing data were imputed by use of k-nearest neighbour 
imputation (k=5) to increase prediction performance.20 We 
did not complete any a­priori hypothesis­based feature 
selection.
We used the EDEN dataset for model development and 
undertook both internal and external validation with 
LOSOCV.21 We fit a logistic regression model by elastic net 
regularisation with variable selection in the caret package22 
using the glmnet package.23 Glmnet fits a generalised 
linear model through penalised maximum likelihood 
(appendix pp 1–2). All the 163 predictor variables were 
used simultaneously with the elastic net regularisation 
model. Each of the 14 EDEN sites was left out once for the 
validation of a model based on the remaining 13 sites 
and trained by use of a ten­fold cross­validation (splits 
balanced by outcome class) over a 10 × 10 grid of 
α and λ hyperparameters, with Breiman’s 1 SE rule.24
We measured average performance across the resulting 
14 best LOSOCV models using receiver operating charac­
teristic (ROC) curve and area under the curve (AUC). 
AUCs, with 95% CIs, were established on the basis of 
U­statistic theory, and permutation testing confirmed 
significance. Representative model accuracy, sensitivity, 
specificity, positive predictive value (PPV), negative 
predictive value (NPV), prognostic summary index (PSI), 
positive likelihood ratio (LR+) and negative likelihood ratio 
(LR–) are presented on the basis of the point on the ROC 
curve corresponding to Youden’s index. We assessed the 
stability (φ) of feature selection in the 14 best LOSOCV 
models using the approach described by Nogueira and 
colleagues,25 where φ lower than 0·4 shows poor agreement 
between the 14 models, 0·4 to 0·75 shows intermediate to 
good agreement, and higher than 0·75 shows excellent 
agreement. We did this model development procedure for 
each of our four binary outcomes.
We assessed the relatedness of the four models by 
computing the Yule ϕ correlation between the four 
outcomes, computing the Pearson correlation between 
probability outputs of the four logistic regression models, 
and assessing the prediction performance when using 
the probability outputs of one model as predictors of 
outcome for the other three models with LOSOCV 
(appendix pp 6–7). We used the shared predictor variables 
among the top variables for the four models to build 
generalised linear models for external validation. 
For external (geographical and temporal) validation of 
the prediction models, we used the Scottish and OPUS 
datasets. For each outcome, we took the shared variables 
across both the EDEN and the external validation dataset 
from the top predictor variables determined during 
model development (those selected in all 14 LOSOCV 
models; figure 1). We standardised these variables 
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In employment, education, or training at baseline
PAS client general employed or at school 
Qualification level 
GAF disability total 
Main income source is salary or wage 
In education at baseline  
Main income source is state benefits 
Length of time since most recent self-harm
Any time spent per week doing childcare activities 
PAS client general degree of interest in life 
PAS client general education
Any time spent per week doing sport activities 
In voluntary employment at baseline 
Ethnicity—white British
First contact with EIS was with police
In paid employment at baseline 
Calgary Depression Scale total 
GAF total
PANSS P2—conceptual disorganisation
Main income source is something other than family, 
salary, or benefits
PANSS G13—disturbance of volition
Most serious self-harm is with knife or razor
Adjusted DUP in days
PAS client childhood sociability withdrawal 
GAF symptoms total
Ethnicity—Pakistani 
Housing type is own home or parents’ home
Sleeps for 8 h or more each day
Family member suggested care
PAS client general job change or interrupted school 
attendance
In receipt of any state benefits
PANSS N6—lack of spontaneity 
Help by friend or relative around the house in last
3 months 
Housing type is rented
Most serious violence victim gender was male
Any help by friend or relative in last 3 months
Contact with criminal justice services in last 3 months
PANSS G11—poor attention
EQ-5D-3L anxiety or depression 
PAS client general job change interrupted school 
attendance 
PANSS G2—anxiety
History of amphetamine use 
EQ-5D-3L mobility 
PANSS P3—hallucinatory behaviour
PAS client early adolescence sociability withdrawal 
Housing type is own home or parents’ home 
PAS client early adolescence social sexual aspects 
EQ-5D-3L health thermometer 
Education level 
Qualification level 
Any first degree relative with schizophrenia 
First contact with EIS was with police
Main income source is salary or wage 
PANSS G11—poor attention
EQ-5D-3L UK TTO index
PAS client general energy level 
PANSS P2—conceptual disorganisation
Initial appointment attended by client and family 
PANSS P5—grandiosity
PANSS G6—depression
GAF total 
History of ketamine use 
History of cocaine use 
Number of previous admissions
PAS client late adolescence sociability withdrawal
Main income source is state benefits 
Any time spent per week doing housework activities 
PANSS P6—suspiciousness
Living with parents or guardian
Most serious self-harm is with knife or razor
Most serious self-harm is with overdose, drugs, or 
alcohol
PANSS P7—hostility 
Never self-harmed
PANSS N6—lack of spontaneity
Help by friend or relative around the house in last 
3 months
Housing type is rented
Adjusted DUP in days
PANSS N5—difficulties in abstract thinking
Male sex
History of LSD use
Number of second-degree relatives with a 
psychiatric family history
History of cannabis use
Figure 1: Top prediction variables for each outcome
Top predictor variables selected by elastic net regularisation across all 14 LOSOCV models for each outcome, 
ordered by their mean rank across the 14 models by absolute coefficient magnitude, along with their direction of 
effect (red is negative, grey is positive). PANSS=Positive And Negative Symptom Scale. GAF=Global Assessment of 
Functioning scale. DUP=Duration of Untreated Psychosis. PAS=Premorbid Adjustment Scale. LSD=Lysergic acid 
diethylamide. EQ-5D-3L=3-level European Quality of Life 5 Dimensions Index. UK TTO=time trade-off index based 
on UK population norms. EIS=Early Intervention Service. LOSOCV=leave-one-site-out cross-validation.
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separately on each dataset before model fitting; therefore, 
we were able to assess EDEN model performance on the 
validation dataset even though some shared variables 
were measured on different scales. Afterwards, we used 
the entire EDEN dataset to fit a generalised linear 
model by maximum likelihood estimation (without 
regularisation) using these shared top predictor variables 
(having found no improvement in performance during 
initial scoping with more complex classifiers, including 
linear and radial support vector machines, elastic net, 
and random forest). We confirmed that the internal–
external validation performance on the EDEN dataset 
remained robust with the new model using only the 
shared top predictor variables. The internally–externally 
validated EDEN model was then externally validated on 
the external dataset, with performance reported as 
already outlined. This process was repeated separately 
for the Scottish datasets and the OPUS dataset (figure 2).
All statistical analyses were done with R, and the code 
is available online. The comparison between EDEN, 
Scottish, and OPUS samples (demographic and social 
variables) is provided in the appendix (p 2).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
We included only participants for whom outcome data 
were available (table 1). In the EDEN studies, 673 (66%) of 
1027 patients had complete symptom remission outcome 
data, 829 (81%) had com plete social recovery outcome 
data, 807 (79%) had com plete vocational recovery outcome 
data, and 729 (71%) had complete QoL outcome data. In 
the Scottish studies, 131 (81%) of 162 patients had complete 
symptom remission outcome data, 142 (88%) had complete 
vocational recovery outcome data, and 47 (59%) of 
79 had complete QoL outcome data. In the OPUS trial, 
338 (58%) of 578 patients had complete symptom 
remission outcome data, 518 (90%) had complete social 
recovery outcome data, 553 (96%) had complete vocational 
recovery outcome data, and 226 (39%) had complete QoL 
outcome data. 15–39% of patients were missing outcomes 
data on model performance at 1 year for training cohorts 
Development sample—EDEN
2005–10
1 site 13 sites
Model
Internally–externally
validated model
External validation
Internal–external
cross-validation
2006–09
2011–14
1998–
2000
Validation sample—Scottish Validation sample—OPUS
Figure 2: Analysis pipeline
Elastic net model development and internal–external validation using a leave-one-site-out cross-validation in the EDEN sample. Internally–externally validated 
generalised linear models were constructed with use of top predictors shared between the EDEN and Scottish datasets, and the EDEN and OPUS datasets. These were 
then externally validated on the Scottish datasets and the OPUS dataset.
Training data 
(EDEN studies)
Validation data 
(Scottish studies)
Validation data 
(OPUS trial)
p value
Symptom remission 320/673 (48%) 66/131 (50%) 121/338 (36%) 0·0006*
Social recovery 388/829 (47%) NA 73/518 (14%) <0·0001*
Vocational recovery 436/807 (54%) 59/142 (42%) 173/553 (31%) <0·0001*
Quality of life 328/729 (45%) 23/47 (49%) 113/226 (50%) 0·39
Data are n/N (%). NA=not applicable. *Significant differences (determined with Pearson’s χ² test) of rates of positive 
outcomes between the cohorts, after Holm-Bonferroni correction.
Table 1: Outcome data for training and validation cohorts
For the R code see 
https://github.com/
samleighton87/EDEN_R_Code
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and for validation cohorts these values were 4–61% for 
OPUS and 19–61% for Scottish studies.
During internal cross­validation with all the 163 predictor 
variables simultaneously, all of our four models had AUCs 
higher than 0·700, significantly better than chance 
(p<0·0001; figure 3, table 2). The accuracy achieved by the 
four models was higher than AUC 0·65, and the PSI of 
the four models was higher than 0·31, indicating a 
31% additional gain in prediction certainty.26 The stability 
of feature selection in the 14 LOSOCV models was 0·54 for 
the remission model, 0·67 for the social recovery model, 
0·71 for the vocational recovery model, and 0·70 for the 
QoL model (appendix p 7).
The correlation of the probability outputs of the 
four models was higher than the correlation of the 
respective outcomes that they were trained to predict. 
Each model predicted its outcome best, but they also 
significantly predicted each of the other three outcomes, 
with a lower level of performance (appendix pp 6–7).
The top predictors for the four models selected by the 
elastic net model are provided in figure 1. The four models 
included predictor variables ranging from demographic 
A
AUC 0·703 (95% CI 0·664–0·742)
p<0·0001
0
0·2
0·4
0·6
0·8
1·0
B
AUC 0·731 (95% CI 0·697–0·765)
p<0·0001
Se
ns
iti
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ty
C
1·0 0·8 0·6 0·4 0·2 0
Specificity
AUC 0·736 (95% CI 0·702–0·771)
p<0·0001
0
0·2
0·4
0·6
0·8
1·0
D
1·0 0·8 0·6 0·4 0·2 0
Specificity
AUC 0·704 (95% CI 0·667–0·742)
p<0·0001
Se
ns
iti
vi
ty
Figure 3: ROC curves showing internal–external LOSOCV model performance in the EDEN dataset for 1-year symptom recovery (A), social recovery (B), 
vocational recovery (C), and quality of life (D) models
ROC=receiver operating characteristic. LOSOCV=leave-one-site-out cross-validation. AUC=area under the curve.
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characteristics, family history, premorbid functioning, 
baseline education and employment status, social factors, 
duration of untreated psychosis, and baseline symptoms 
(appendix pp 2–6). These models had similar performance 
to the elastic net model built with use of the 163 predictor 
variables on LOSOCV. The external validation perfor­
mance of the generalised linear models was significantly 
better than chance, with AUCs higher than 0·67 for 
symptom remission and QoL outcomes, and higher than 
0·86 for the vocational recovery outcome in the Scottish 
datasets. The external validation performance of the 
generalised linear models had AUCs of 0·61 for remis­
sion, 0·57 for social recovery, and 0·66 for vocational 
recovery outcomes in the OPUS dataset. The AUC of the 
generalised linear model for QoL was not statistically 
significant (table 2, appendix pp 11–12). We did external 
validation performance for the two groups of the OPUS 
trial (appendix pp 9–10). Model performance was better in 
the standard treatment group for remission and social 
recovery than for the other outcomes, whereas in the 
intervention group, performance was better for vocational 
recovery.
Discussion
In this study, we developed outcome prediction models 
for remission and recovery for people with first­episode 
psychosis using baseline sociodemographic and clinical 
variables, and we internally cross­validated the models 
with a large naturalistic cohort study (EDEN study). We 
externally validated the prediction models on patients 
from three studies: two longitudinal cohort studies of 
patients with first­episode psychosis (Scottish studies) 
and a randomised control trial of specialised assertive 
intervention treatment versus standard treatment (OPUS). 
The predictive performance of the models were in the 
range of values for established calculators in use for 
predicting risk of cardiovascular diseases (AUC 0·71–0·76)27 
and cancer (0·57–0·72).28–30 The PSIs indicated that our 
prediction models provided a 31–37% increase in prog­
nostic certainty compared with that of pre­test probabilities 
at 1 year.
We developed prediction models for multiple outcomes, 
including remission and recovery (social and vocational 
recovery and QoL), in recognition of the fact that 
intervention strategies might be distinct for each outcome,31 
even though each of our models was able to accurately 
predict other outcomes significantly better than chance, 
albeit with reduced performance. Our prediction model 
for social recovery had similar performance (AUC 0·731) 
to that of Koutsouleris and colleagues’8 model (balanced 
accuracy 0·71), though their study was limited by the 
absence of a true external validation. Our model 
performance for the remission outcome (AUC 0·703 
[95% CI 0·664–0·742]) was better than that of Leighton 
and colleagues’9 model (0·635–0·670), whereas their 
model performance for vocational recovery was better than 
that of our model. In our study, the stability of feature 
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selection in the 14 LOSOCV models (0·54 for the remission 
model, 0·67 for the social recovery model, 0·71 for the 
vocational recovery model, and 0·70 for the QoL model) 
indicates an intermediate to good strength of agreement 
within each of the four prediction models.25
The external validation performance of the prediction 
models was similar to that of the training dataset for the 
Scottish datasets, although the performance was reduced 
in the OPUS dataset. Several possible explanations exist 
for this difference. The external validation models were 
necessarily built with use of shared variables alone, not 
with all the top identified predictor variables. However, a 
repeat internal validated LOSOCV perfor mance with 
models using just the shared variables remained similar 
in the EDEN dataset. The way outcomes (and some 
predictors) were measured differed between the datasets: 
remission was defined with Andreasen criteria, but with 
use of PANSS for EDEN and Scottish datasets and 
SAPS–SANS (Scale for the Assessment of Negative 
Symptoms) for the OPUS dataset; social functioning was 
defined by GAF for EDEN, but by use of the mean of GAF 
symptoms and GAF disability for OPUS; and for QoL, 
EDEN used EQ­5D­3L, but the other three datasets used 
WHO QoL. The measurement of vocational recovery 
outcomes was similar across the datasets, and the fact that 
this model performed best in external validation could 
reflect this. Furthermore, we found significant differences 
in the balance of remission and recovery outcome rates 
between all datasets, although the OPUS dataset had 
much fewer remission and recovery outcomes than those 
of the other datasets. This finding might be explained by 
the differing timeframes of data collection and the fact 
that the EDEN and Scottish datasets were collected from 
patients in early­intervention services, whereas OPUS was 
a randomised controlled trial of intensive versus standard 
treatment. Contrary to our expectation, the validation 
performance was better for the remission and social 
recovery outcomes for the standard treatment group of 
the OPUS trial. The validation performance for the 
vocational recovery model was better for the intensive 
treatment group, which is similar to the performance in 
the training dataset. Taken together, these issues are 
unavoidable in the context of our analyses being 
opportunistic and post­hoc, with use of existing datasets. 
However, the fact that model performance was 
significantly better than chance on external validation 
(except for QoL in OPUS), despite these differences, is 
very promising for the ability of such methods to withstand 
heterogeneous data in real­world clinical settings.
Our analysis has several strengths. The data for the 
model development were derived from one of the largest 
naturalistic cohort studies in patients with first­episode 
psychosis treated in early­intervention services. We used 
LOSOCV for model development and internal validation. 
We found the stability of the feature selection with 
LOSOCV for 14 sites to have intermediate to good level of 
agreement. Furthermore, we externally validated the 
models in three independent datasets with different time 
periods, geographical regions, and recording methods. 
We used strict operationalised outcome criteria to define 
symptomatic outcomes and developed prediction models 
for multiple outcomes. Each of the individual prediction 
models predicted the other three outcomes better than 
chance, although with reduced performance. An 
argument exists for using one prediction model to predict 
multiple outcomes, although this would come with a 
trade­off of marginally reduced performance and needs 
further testing in prospective clinical trials.
Our study also has several limitations. About 49% of 
eligible patients consented to participate in the EDEN 
study, which might affect the generalisability of our 
prediction models to all patients with first­episode 
psychosis. However, participants who did not consent 
had characteristics largely similar at baseline to those of 
individuals who consented to participate.10 Despite this, 
we cannot assume that the models developed with data 
from the patients included in the EDEN study would 
have a better performance than chance in individuals not 
included in the EDEN study sample. The effect of 
missing outcomes data on model performance was not 
trivial in patients at 1 year for training cohorts (15–39%) 
and for validation cohorts (OPUS 4–61%; Scottish studies 
19–61%). This effect might introduce bias and affect the 
generalisability of our results. Importantly, our models 
have not been validated for prediction after baseline as 
treatment progresses. Future studies could consider 
building models that account for change over time or in 
response to treatment (eg, dynamic Bayesian networks 
with continuous retraining). We did not collect cognitive 
and physical biomarkers of illness, including blood 
samples and neuroimaging, which previous studies have 
highlighted as potentially important for generating 
accurate predictions.32 The duration criteria for recovery 
has been proposed to be at least 2 years.33 However, the 
criteria used in our analysis for recovery outcomes were 
much narrower and, for three of four measures, were 
based on point outcomes (GAF; employment, education, 
or training status; and QoL) at 1 year. The prevalence of 
recovery in our training cohort was similar to that 
reported in a large meta­analysis,4 but higher than that 
reported in another meta­analysis,2 which might also 
affect the generalisability of our model.
The decision making process to determine which 
interventions to use and for how long in the treatment of 
patients with a first­episode psychosis is based on clinical 
intuition. We are not aware of evidence assessing how 
accurate clinicians using baseline information are at 
predicting 1­year outcomes for psychosis, although it 
has been shown that clinicians are poor at predicting 
outcomes in depression.34,35 Clinicians working with 
patients with first­episode psychosis might benefit from 
a reliable and methodologically robust tool to identify 
individuals with likelihood of a good or poor outcome 
at initial clinical contact, so that the information on 
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outcome prediction can be used alongside clinical 
judgment for stratification of treatment.
Patients with good outcomes are likely to need a different 
set of interventions and duration of treatment compared 
with patients with poorer outcomes. If outcome prediction 
models are developed into clinically applicable tools after 
further rigorous testing of their usefulness in a prospective 
clinical trial, they could assist in clinical decision making, 
leading to better use of clinical resources by providing 
targeted interventions based on individual predictions of 
patient outcomes. Guidelines could be developed in 
consultation with stakeholders on how to put such tools 
into practice to facilitate a stepped model of care. Future 
work should identify, in a prospective clinical trial, whether 
one prediction model might accurately predict multiple 
outcomes and whether it is possible to update the 
prediction models prospectively over time and in response 
to different interventions. Whether the addition of other 
predictors, including biomarkers, will improve prediction 
accuracy of the models remains to be tested.
In our machine learning analysis of a longitudinal 
cohort of patients with first­episode psychosis treated in 
early­intervention services, we were able to show that 
multiple outcomes can be reliably predicted for patients 
by use of baseline demographic and clinical variables at 
1 year, with external generalisability. Our prediction 
models have similar discriminatory power to other 
available predictive models.8,9 Our models benefit from 
being developed with use of a naturalistic cohort study 
and externally validated in a cohort study and a randomised 
control trial, together with the use of readily available 
clinical data and, to our knowledge, the largest sample 
size used in a machine learning study of first­episode 
psychosis to date. Furthermore, to our knowledge, our 
study represents the first published evidence for the use of 
machine learning models of QoL outcome in patients 
with a first­episode psychosis.
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